Drugs that contain Dasabuvir Sodium; Ombitasvir; Paritaprevir; Ritonavir

1. List of Viekira Xr drug patents

VIEKIRA XR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Sep, 2028

(5 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(6 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 4 months from now)

US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 4 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof
Nov, 2028

(5 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(8 years from now)

US10201541 ABBVIE INC Compositions and methods for treating HCV
May, 2032

(9 years from now)

US10201584 ABBVIE INC Compositions and methods for treating HCV
May, 2032

(9 years from now)

US8680106 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8685984 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8466159 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US8492386 ABBVIE INC Methods for treating HCV
Sep, 2032

(9 years from now)

US10105365 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(11 years from now)

US9744170 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(11 years from now)

US9333204 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(11 years from now)

Market Authorisation Date: 22 July, 2016

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VIEKIRA XR family patents

110

United States

30

European Union

27

Japan

26

Spain

24

China

19

Portugal

18

Denmark

18

Canada

16

Hong Kong

16

Poland

16

Taiwan, Province of China

15

Slovenia

15

Croatia

13

South Africa

13

Mexico

13

Germany

13

Cyprus

13

Chile

12

Uruguay

12

Argentina

12

Korea, Republic of

12

New Zealand

11

Hungary

EA

11

EA

10

Brazil

10

Peru

10

United Kingdom

9

Israel

9

Dominican Republic

8

Lithuania

8

Guatemala

8

Ecuador

8

Ukraine

8

RS

7

Australia

7

Singapore

6

Norway

5

Costa Rica

4

Turkey

4

Colombia

4

Sweden

4

Malaysia

4

Netherlands

4

Luxembourg

3

Austria

3

Philippines

2

Russia

2

Switzerland

2

ME

1

El Salvador

1

San Marino

1

Georgia

1

Panama

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in